Evidence map›Paper›PMID 37242563›Full record

ArticlePharmaceutics2023

Glycovaccine Design: Optimization of Model and Antitubercular Carrier Glycosylation via Disuccinimidyl Homobifunctional Linker.

Sara Tengattini, Davide Rubes, Massimo Serra, Luciano Piubelli, Loredano Pollegioni, Enrica Calleri, Teodora Bavaro, Gabriella Massolini, Marco Terreni, Caterina Temporini

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sara TengattiniDepartment of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.ORCID 0000-0002-8584-5883
Davide RubesDepartment of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.ORCID 0000-0002-8557-4577
Massimo SerraDepartment of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.ORCID 0000-0002-6724-4355
Luciano PiubelliDepartment of Biotechnology and Life Sciences, University of Insubria, Via Dunant 3, 21100 Varese, Italy.
Loredano PollegioniDepartment of Biotechnology and Life Sciences, University of Insubria, Via Dunant 3, 21100 Varese, Italy.ORCID 0000-0003-1733-7243
Enrica CalleriDepartment of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.
Teodora BavaroDepartment of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.ORCID 0000-0002-1286-2535
Gabriella MassoliniDepartment of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.
Marco TerreniDepartment of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.
Caterina TemporiniDepartment of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.
University of Pavia · ITUniversity of Insubria · IT

Funding

Italian Ministry of Health T4-CN-02
6 · The paper itself

Abstract

Conjugation via disuccinimidyl homobifunctional linkers is reported in the literature as a convenient approach for the synthesis of glycoconjugate vaccines. However, the high tendency for hydrolysis of disuccinimidyl linkers hampers their extensive purification, which unavoidably results in side-reactions and non-pure glycoconjugates. In this paper, conjugation of 3-aminopropyl saccharides via disuccinimidyl glutarate (DSG) was exploited for the synthesis of glycoconjugates. A model protein, ribonuclease A (RNase A), was first considered to set up the conjugation strategy with mono- to tri- mannose saccharides. Through a detailed characterization of synthetized glycoconjugates, purification protocols and conjugation conditions have been revised and optimized with a dual aim: ensure high sugar-loading and avoid the presence of side reaction products. An alternative purification approach based on hydrophilic interaction liquid chromatography (HILIC) allowed the formation of glutaric acid conjugates to be avoided, and a design of experiment (DoE) approach led to optimal glycan loading. Once its suitability was proven, the developed conjugation strategy was applied to the chemical glycosylation of two recombinant antigens, native Ag85B and its variant Ag85B-dm, that are candidate carriers for the development of a novel antitubercular vaccine. Pure glycoconjugates (≥99.5%) were obtained. Altogether, the results suggest that, with an adequate protocol, conjugation via disuccinimidyl linkers can be a valuable approach to produce high sugar-loaded and well-defined glycovaccines.

Indexed as

Ag85B antigenantitubercular vaccineschemical glycosylationdisuccinimidyl linkersglycoconjugate characterizationglycoconjugate vaccinesglycosylation optimization

Identifiers

PMID37242563
PMCPMC10223089
OpenAlexW4366827588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.